8-K: 10x Genomics Reports Mixed Q1 2025: Revenue Up, Workforce Reduced Amidst Funding Uncertainty

10x Genomics announced its Q1 2025 financial results, featuring revenue growth boosted by a patent settlement, alongside cost-cutting measures including a workforce reduction due to uncertainty in research funding.

Summary

• 10x Genomics reported a 10% increase in revenue for Q1 2025, reaching $154.9 million, compared to $141.0 million in the same period last year.
• This includes $16.8 million from a patent litigation settlement; excluding this, revenue decreased by 2% year-over-year to $138.1 million, primarily due to lower instrument revenue.
• The company's gross margin increased to 68% from 66% year-over-year, driven by higher license and royalty revenue and lower manufacturing costs.
• Excluding the impact of license and royalty revenue, the gross margin was 64%.
• Operating expenses decreased by 6% to $144.8 million, primarily due to a $9.2 million gain on settlement related to the litigation settlement.
• The operating loss was $39.3 million, an improvement from the $61.5 million loss in the prior year period.
• Net loss improved to $34.4 million from $59.9 million year-over-year.
• 10x Genomics ended the quarter with $426.9 million in cash, cash equivalents, and marketable securities.
• The company is implementing a plan to reduce operating expenses by more than $50 million in 2025, including an 8% workforce reduction.
• Due to uncertainty in U.S. academic and government research funding, 10x Genomics is withdrawing its full-year revenue guidance and providing quarterly guidance instead.
• For Q2 2025, the company expects revenue to be in the range of $138 million to $142 million, representing 1% sequential growth at the midpoint, excluding the license and royalty revenue from the settlement.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased overall, the underlying performance excluding the settlement was weaker, and the company is facing funding uncertainty and implementing cost-cutting measures. The strong cash position is a positive, but the withdrawn guidance is concerning.

Positives

• Overall revenue increased by 10% year-over-year.
• Gross margin improved to 68%.
• Operating expenses decreased by 6%.
• Net loss decreased significantly from the prior year.
• The company maintains a strong cash position with $426.9 million in cash and marketable securities.
• Cost reduction initiatives are being implemented to strengthen the balance sheet.

Negatives

• Excluding the patent litigation settlement, revenue decreased by 2% year-over-year.
• Instrument revenue experienced a significant decrease.
• Full-year revenue guidance was withdrawn due to uncertainty in U.S. academic and government research funding.
• The company is implementing a workforce reduction of approximately 8%.

Risks

• Uncertainty in U.S. academic and government research funding could continue to impact revenue.
• The workforce reduction may lead to unforeseen costs or operational challenges.
• Actual costs associated with the workforce reduction may differ materially from current estimates of $5.5 million to $6.5 million.
• The company may incur additional costs not currently contemplated due to events associated with the workforce reduction.
• Reliance on academic and government funding makes the company vulnerable to policy changes.

Future Outlook

Due to uncertainty in U.S. academic and government research funding, 10x Genomics is withdrawing its full-year revenue guidance and providing quarterly guidance instead; for Q2 2025, revenue is expected to be in the range of $138 million to $142 million, representing 1% sequential growth at the midpoint, excluding the license and royalty revenue from the settlement.

Management Comments

• Serge Saxonov, Co-founder and CEO, stated that customer enthusiasm and improving consumables trends reinforce their conviction in the technology and potential of Single Cell and Spatial.
• Saxonov also noted that the company is temporarily moving to quarterly guidance due to uncertainty in U.S. academic and government research funding and is prioritizing cost reduction initiatives.

Industry Context

The life science tools industry is facing headwinds due to macroeconomic uncertainty and funding constraints, particularly in academic and government research. 10x Genomics' actions to reduce costs and focus investments reflect a broader trend among companies in the sector to adapt to these challenges.

Comparison to Industry Standards

• Competitors like Illumina and Pacific Biosciences also face similar challenges related to research funding and macroeconomic conditions.
• Illumina, for example, has also implemented cost-cutting measures and adjusted its guidance in response to market conditions.
• The 68% gross margin is relatively strong compared to some peers, but the decrease in instrument revenue is a concern shared by other companies in the industry.
• The company's cash position of $426.9 million provides a buffer compared to companies with less liquidity.

Stakeholder Impact

• Shareholders may be concerned about the withdrawn revenue guidance and workforce reduction.
• Employees are impacted by the workforce reduction.
• Customers may experience changes in service or support due to the cost-cutting measures.
• Suppliers may see reduced orders as the company reduces operating expenses.

Next Steps

• The company will host a conference call on May 8, 2025, to discuss the financial results and business developments.
• The company expects to recognize costs associated with the workforce reduction in the second quarter of 2025 and pay them by the end of the third quarter of 2025.
• The company will continue to monitor U.S. academic and government research funding to assess future guidance.

Key Dates

Keywords

10x Genomics, Financial Results, Q1 2025, Revenue, Workforce Reduction, Guidance, Single Cell, Spatial Biology, Patent Litigation, Operating Expenses